MedPath

Glatopa

These highlights do not include all the information needed to use safely and effectively. See full prescribing information for . GLATOPA (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996

Approved
Approval ID

5f01e40a-b6f6-40fb-b37c-3d06f1428e86

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 6, 2023

Manufacturers
FDA

Sandoz Inc

DUNS: 005387188

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Glatiramer Acetate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0781-3250
Application NumberANDA206921
Product Classification
M
Marketing Category
C73584
G
Generic Name
Glatiramer Acetate
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateOctober 31, 2018
FDA Product Classification

INGREDIENTS (2)

GLATIRAMER ACETATEActive
Quantity: 40 mg in 1 mL
Code: 5M691HL4BO
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT

Glatiramer Acetate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0781-3234
Application NumberANDA090218
Product Classification
M
Marketing Category
C73584
G
Generic Name
Glatiramer Acetate
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateOctober 31, 2018
FDA Product Classification

INGREDIENTS (2)

GLATIRAMER ACETATEActive
Quantity: 20 mg in 1 mL
Code: 5M691HL4BO
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Glatopa - FDA Drug Approval Details